David A Sallman Selected Research

David A Sallman Research Topics

Disease

30	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2024 - 12/2016
22	Neoplasms (Cancer) 05/2024 - 11/2007
15	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 02/2024 - 01/2014
6	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 01/2023 - 01/2020
4	Anemia 11/2023 - 01/2022
3	Hematologic Neoplasms (Hematological Malignancy) 01/2024 - 01/2017
3	Febrile Neutropenia 04/2023 - 10/2021
3	Primary Myelofibrosis (Myelosclerosis) 01/2019 - 12/2017
2	Disease Progression 12/2023 - 01/2017
2	Leukopenia 04/2023 - 10/2021
2	Neutropenia 01/2023 - 10/2021
2	Leukocytosis (Pleocytosis) 10/2021 - 12/2017
2	Splenomegaly 03/2018 - 12/2017
1	Pleural Effusion (Pleural Effusions) 04/2024
1	Cytopenia 02/2024
1	Residual Neoplasm 02/2024
1	Thrombocytopenia (Thrombopenia) 04/2023
1	Multiple Myeloma 03/2023
1	Hypersensitivity (Allergy) 01/2023
1	Bites and Stings (Sting) 01/2022
1	Inflammation (Inflammations) 01/2022
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022
1	Leukemia 11/2021
1	Pathologic Complete Response 01/2020
1	Disease Susceptibility (Diathesis) 10/2015
1	Aplastic Anemia (Anemia, Hypoplastic) 01/2014
1	Autoimmune Diseases (Autoimmune Disease) 04/2009
1	Prostatic Neoplasms (Prostate Cancer) 11/2007

Drug/Important Bio-Agent (IBA)

8	Azacitidine (5 Azacytidine)FDA Link 12/2023 - 01/2020
5	eprenetapoptIBA 04/2023 - 01/2020
4	Lenalidomide (CC 5013)FDA Link 01/2023 - 01/2014
4	Proteins (Proteins, Gene)FDA Link 01/2023 - 04/2009
3	venetoclaxIBA 02/2024 - 01/2022
3	magrolimabIBA 11/2023 - 12/2020
3	InflammasomesIBA 01/2022 - 12/2016
3	ruxolitinibIBA 11/2021 - 12/2017
2	Monoclonal AntibodiesIBA 11/2023 - 01/2023
2	DNA (Deoxyribonucleic Acid)IBA 05/2023 - 01/2022
2	Chimeric Antigen ReceptorsIBA 03/2023 - 01/2022
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2023 - 01/2020
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2018
2	ClusterinIBA 06/2010 - 11/2007
2	Docetaxel (Taxotere)FDA Link 06/2010 - 11/2007
1	Dasatinib (BMS 354825)FDA Link 04/2024
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2024
1	ivosidenibIBA 01/2024
1	Core Binding Factors (Core-Binding Factor)IBA 12/2023
1	Hemoglobins (Hemoglobin)IBA 11/2023
1	NK Cell Lectin-Like Receptor Subfamily KIBA 03/2023
1	LigandsIBA 03/2023
1	proto-oncogene proteins pimIBA 01/2023
1	luspaterceptIBA 01/2023
1	HematinicsIBA 01/2023
1	Cytokine Receptors (Cytokine Receptor)IBA 11/2022
1	RNA (Ribonucleic Acid)IBA 11/2022
1	Serine (L-Serine)FDA Link 09/2022
1	EnzymesIBA 09/2022
1	Glycine (Aminoacetic Acid)FDA LinkGeneric 09/2022
1	Glutathione (Reduced Glutathione)IBA 09/2022
1	Carrier Proteins (Binding Protein)IBA 01/2022
1	Biological FactorsIBA 01/2022
1	Erythropoietin FDA Link 01/2022
1	GATA Transcription FactorsIBA 01/2022
1	axicabtagene ciloleucelIBA 01/2022
1	RNA Splicing FactorsIBA 01/2022
1	Peptide Hydrolases (Proteases)FDA Link 01/2022
1	cyclic guanosine monophosphate-adenosine monophosphateIBA 01/2022
1	MDS 11IBA 10/2021
1	Immune Checkpoint InhibitorsIBA 01/2021
1	Daunorubicin (Cerubidine)FDA LinkGeneric 01/2020
1	lenzilumabIBA 01/2020
1	selinexorIBA 01/2020
1	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2020
1	Oncogene Proteins (Oncogene Protein)IBA 01/2019
1	glasdegibIBA 01/2019
1	Glucose (Dextrose)FDA LinkGeneric 09/2018
1	PrionsIBA 09/2018
1	Hydroxyurea (Hydrea)FDA LinkGeneric 12/2017
1	Thalidomide (Thalomid)FDA Link 12/2017
1	API 2IBA 06/2010
1	ResveratrolIBA 11/2007

Therapy/Procedure

30	Therapeutics 04/2024 - 10/2015
3	Drug Therapy (Chemotherapy) 01/2022 - 01/2017
2	Immunotherapy 05/2024 - 01/2017
1	Drug Tapering 10/2021
1	Precision Medicine 09/2021
1	Induction Chemotherapy 01/2020
1	Transplantation 01/2019
1	Salvage Therapy 03/2018